Physician profile
Robert K Druger
NPI 1013984723
$10,448.82
in general payments reported to CMS, 2019-2025
22 companies · $2,130 in 2025
The $2,130 reported for 2025 was more than what 89% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,322 · 2020: $851 · 2021: $988 · 2022: $2,086 · 2023: $1,500 · 2024: $1,572 · 2025: $2,130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,201.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,200.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $5,836.72 | 2019-2025 | Clareon, Rocklatan, Centurion |
| Sight Sciences, INC. | $652.06 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $528.93 | 2019-2025 | Cequa |
| Novartis Pharmaceuticals Corporation | $523.93 | 2019-2023 | |
| Oyster Point Pharma, INC. | $394.32 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Amgen INC. | $375.65 | 2024-2025 | Tepezza |
| Bausch & Lomb Americas INC. | $342.63 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Glaukos Corporation | $315.80 | 2025 | Idosetr, Istent, Istent Infinite |
| Abbvie INC. | $182.35 | 2022-2025 | Durysta |
| Ocular Therapeutix, INC. | $171.34 | 2023-2024 | Dextenza |
| Harrow Eye, LLC | $171.14 | 2023-2025 | Vevye, Iheezo |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $165.02 | 2019-2021 | |
| Horizon Therapeutics Plc | $151.39 | 2022-2023 | Tepezza |
| Eyevance Pharmaceuticals LLC | $132.15 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $113.96 | 2024-2025 | Xdemvy |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $97.56 | 2021-2022 | |
| Thea Pharma INC. | $84.21 | 2025 | Iyuzeh |
| Biotissue Holdings INC. | $61.31 | 2019 | |
| Allergan, INC. | $48.58 | 2021-2022 | |
| Shire North American Group INC | $42.69 | 2019 | |
| Rayner Intraocular Lenses Limited | $31.84 | 2023-2024 | Rayone Aspheric, Rayone Spheric, Rayone Emv |
| Omeros Corporation | $25.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Druger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.